Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Acromegaly Drugs Price Analysis and Strategies - 2016" report to their offering.
Acromegaly Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Acromegaly market.
The research answers the following questions:
- What are the key drugs marketed for Acromegaly and their clinical attributes? How are they positioned in the Global Acromegaly market?
- What are the unit prices and annual treatment cost for Acromegaly therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Acromegaly drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Acromegaly?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Acromegaly including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Acromegaly
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Acromegaly market
- Acromegaly Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Acromegaly New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/zj9b22/acromegaly_drugs
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs


Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 



